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Abstract:   
These studies used targeted temporal food restriction (TTFR; access to chow limited to two 
hours/day) in rats to model the eating pattern of some obese people who restrict their consumption 
of food to the evening, when activity is typically less, and eat little or no breakfast or lunch.  I tested 
the hypothesis that Estradiol benzoate (EB)-treatment suppresses feeding and decreases body 
weight during TTFR, as it does during ad libitum feeding conditions, and investigated central 
nervous system (CNS) and peripheral mechanisms of these effects in TTFR rats that were fed or 
fasted on test days.  
 Ovariectomized (OVX) rats lost weight during TTFR, but the weight loss was greater in 
EBtreated rats. However, both EB-treated and oil vehicle-treated (OIL) control rats ate comparable 
amounts.  To investigate central mechanisms of EB effects during TTFR, I examined neural 
interactions in the hindbrain nucleus of the solitary tract (NTS), where vagal afferents from the 
gastrointestinal tract terminate.  cFos labeling in the NTS was increased in TTFR-fed rats, 
indicating neuronal activation associated with consumption of a meal. However, cFos 
immunolabeling was not affected by EB treatment.  Moreover, numbers of the α subtype of 
estrogen receptors in the NTS were not affected by hormone treatment or feeding condition.    
To investigate peripheral mechanisms underlying EB effects during TTFR, we assessed 
carbohydrate and fat metabolism, and related hormones.  Plasma insulin was not different between 
hormone groups.  Plasma glucose was in the physiological range, though lower in EB-treated rats. 
Liver glycogen was at physiological levels in ad libitum conditions, decreased as expected in TTFR-
fasted groups, and was partially restored in TTFR-fed groups.  Plasma leptin was not different 
between hormone groups, decreased as expected in TTFR-fasted groups, and then was partially 
restored in TTFR-fed groups. Plasma triglycerides (TG) and plasma free fatty acids (FFA) were 
elevated in EB-treated rats.  Adrenal weights and plasma corticosterone were greater in EBtreated 
rats, which may indicate stress associated with TTFR.  In addition, fat metabolism is affected by 
corticosterone, which may explain EB effects on TGs and FFAs and, thus, the differences in body 
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Research into the controls of food intake and body weight is increasingly important as the 
number of overweight and obese Americans continues to rise.  Body weight increases substantially 
in women after menopause (100), an observation that suggests a role for ovarian hormones in 
body weight regulation. Unfortunately, the strategy many women employ to lose weight—
decreasing the amount of calories and/or the number of meals consumed—has limited success, 
particularly over the long-term. Better understanding of the mechanisms by which ovarian 
hormones affect body weight during periods of food restriction, therefore, has the potential to 
provide critical insights into maintaining healthy body weight. Studies using animal models have 
facilitated understanding of the role of ovarian hormones in body weight regulation, and many 
focus on the interactions between body weight and food intake. In reproductively cycling female 
rats, body weight and food intake fluctuate with fluctuations in ovarian hormones  
(48, 52), with decreased body weight and food intake at proestrus when estradiol is greatest. 
Similarly, exogenous estradiol administration to ad libitum fed ovariectomized (OVX) rats 
decreases both food intake and body weight (64, 168).   
Although the control of feeding is complex and multifaceted, estradiol appears to reduce 
feeding by altering peripheral signals, such as leptin, glucose and gastric distention, that           
inhibit food intake or by altering the sensitivity to such signals by the central nervous system (CNS). 
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Vagal afferents from the gastrointestinal (GI) tract terminate in the nucleus of the solitary tract 
(NTS) (33).  Understandably, then, many investigations that sought to determine whether 
estradiol increases inhibitory signals and/or alters the sensitivity to such signals have focused on 
the NTS. Feeding-induced neural activation in the NTS is enhanced by estradiol benzoate (EB) 
treatment (50), suggesting that estradiol does, in fact, augment inhibitory signaling from the gut. 
Moreover, EB effects on feeding and body weight appear to  involve binding to the α subtype of 
the estrogen receptor (ERα) at CNS sites involved in feeding, such as the NTS (115, 162).  ERα are 
also located in the hypothalamus and other brain sites implicated in food intake and body weight.  
There is a lack of consensus about which of these sites is critical for the EB effects on feeding and 
body weight, though the NTS is a likely candidate in these effects.  
In general, previous investigations of estradiol effects on feeding were conducted in rats 
that had ad libitum access to chow. These studies have provided a wealth of information about 
estradiol modulation of the controls of feeding in conditions when chow is freely available (10, 22, 
49, 64). However, limiting food intake to reduce caloric intake is common in diets and other weight 
loss programs (57, 108, 146). Indeed, many obese dieters voluntarily restrict food intake and 
consume only a single large evening meal each day (14, 46, 159).     
 Several studies focused on different aspects of food intake and body weight and showed 
that male rats adapted to temporally targeted food restriction (TTFR) via changes in gastric 
empting or a shift to lipid metabolism with prolonged TTFR. With prolonged TTFR, metabolic 
changes occur that increase lipogenesis in liver and fatty tissue (94) and decrease hepatic glycogen 
depletion (93).  Female rats have been subjected to TTFR in various feeding protocols (feeding for  
2-4hr one or more time per day) (123, 128, 160, 163).  These studies focused on the advantage of  
TTFR-induced diminished insulin release in the progression of breast tumors, the effects of 
mealfeeding on lipogenesis in brown adipose tissue and glycogen and glucose synchronization to 
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the phases of the circadian cycle in TTFR.  However, estrogen effects on the metabolic factors 
during TTFR affecting body weight and food intake have not been investigated in female rats.    
The prevalence of the TTFR strategy for obese and overweight women raises the possibility 
that estradiol may also impact feeding and body weight when food intake is restricted to a single 
time period each day (i.e. TTFR).  Accordingly, we hypothesized that estradiol inhibits feeding and 
reduces body weight in rats during TTFR, as it does during ad libitum conditions.  Therefore our 
goals were to investigate central and peripheral mechanisms of EB effects during TTFR. To assess 
central detection of signals related to food intake and body weight, we examined neural 
interactions in the hindbrain nucleus of the solitary tract (NTS), where vagal afferents from the 
gastrointestinal tract terminate.  We also investigated peripheral mechanisms underlying EB 
effects on food intake and body weight during TTFR, by assessing carbohydrate and fat 
metabolism, as well as related hormones.  Better understanding of the influence of estrogen on 
these factors may have critical implications for understanding the effectiveness of food restriction 

















CHAPTER II  
  
  
LITERATURE REVIEW  
  
Obesity is a major problem in the US (61, 62), especially for women and, in particular, after 
menopause when body weight increases (99).  Women diet to lose weight by decreasing the 
number of meals or the amount of calories consumed, but with variable effectiveness.  Thus, 
animal models of obesity and feeding are critical to greater understanding of the controls of 
eating.  A wealth of previous studies, many in rats, have shown that feeding is influenced by 
hunger, satiety, and physiological mechanisms that link eating with the availability of calories, and 
a with stable body weight (1, 75, 127, 132, 144, 175).  In short, the controls of food intake and 
body weight are complex processes subject to inhibitory and stimulatory signals including gastric, 
hormonal, and metabolic signals, or a combination of these signals.    
In  1925, Wang reported changes in body weight and food intake during the ovarian cycle 
of rats (170) suggesting that ovarian hormones have a role in the control of feeding and body 
weight.  Consistent with this finding, body weight increases after menopause in humans (100) and 
after OVX in rats (8), further supporting the involvement of estrogen and/or progesterone in 
weight control.   Subsequent studies showing that estrogen treatment inhibits food intake and 
body weight gain in ad libitum fed OVX rats (48), point more conclusively to estrogen in the control 
of food intake and body weight.  This effect may be due to estrogen-mediated changes in levels of 
5  
  
any of the inhibitory or excitatory signals that control feeding and body weight.  Alternatively, 
estrogen may alter sensitivity to such signals, via interactions with the CNS.  
CNS, feeding and body weight  
 
Many studies have implicated a number of CNS areas in the regulation of food intake and body 
weight   (15, 16, 113, 154, 158).  Major hypothalamic regions implicated include the arcuate 
nucleus (ARC), from where neurons project anteriorly to other CNS areas involved in the control 
of feeding and body weight, including the paraventricular nucleus (PVN) and the lateral 
hypothalamic area (LHA).  Other hypothalamic regions implicated in regulating food intake include 
the ventromedial nucleus (VMN) and the dorsomedial nucleus (DMN).  The PVN and the LHA are 
part of central autonomic circuits that project to hindbrain areas involved in the control of feeding 
such as the NTS.  At the same time, signals arising from the liver, gastrointestinal tract, and gut 
peptides are transmitted through the vagus nerve to the NTS and the adjacent area postrema 
(AP). These signals are integrated with descending hypothalamic input (154). Finally, circulating 
hormones and metabolites are detected by circumventricular organs (CVOs) such as the hindbrain 
AP and the forebrain subfornical area and organum vasculosum laminae terminalis (OVLT).    
In male rats, c-FOS expression (a marker of neural activation) is increased in the CNS after 
ingestion of meals (141).  The NTS is the hindbrain site at which numerous signals related to the 
control of feeding including leptin, serotonin (5HT), and glucagon-like peptide-1 (GLP-1) (5, 6, 35) 
are processed.  In addition, the anorexigenic neuropeptide oxytocin (OT) regulates gastric motility 
and activity of OT neurons is increased in response to stomach distention or to increased 
osmolality (120). OT neurons in the hypothalamus send projections to two major brainstem sites 
including the dorsal motor nucleus of the vagus (DMV), which provides efferent and afferent vagal 
innervation of the stomach, and the AP, a CVO which lacks a blood brain barrier and monitors 
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peripheral signals.  Thus, these interconnected areas play an important role in the detection of 
feeding-related information, which includes GI motility, plasma hormones, and plasma  
metabolites (74, 107).     
  
Estrogen, estrogen receptor distribution, and regulation of food intake and body weight  
Estrogens act through two types of estrogen receptors (ER): classic nuclear receptors (ERα 
and ERβ) and novel cell membrane receptors (GPR30, ER-X and ERα36). Both types of estrogen 
receptors are expressed both peripherally and in the CNS, with cell- and tissue-specific 
distributions. For example, estrogens from the ovary, interacting with nuclear estrogen receptors, 
play major roles in the regulation of the reproductive system, such as pubertal onset, fertility, and 
the estrous cycling, while estrogens in the CNS protect against insult-induced neuronal damage 
via both nuclear and cell membrane receptors (177, 178).   
In the CNS, both ERα and ERβ are widely distributed and are expressed in both neuronal 
and non-neuronal cell types (89, 109, 131). Although overlapping expression of ERα and ERβ has 
been demonstrated in some brain regions, the levels of expression, as well as the distribution 
patterns of ERα and ERβ, are largely distinct.  The distribution of ERα and ERβ is related to receptor 
function.  ERα is the most abundant subtype in the hypothalamus and amygdala, which are key 
regions involved with neuroendocrine function, and estrogen helps to regulate the autonomic 
nervous system and emotional reactions. ERβ levels are greatest in the hippocampus, and cerebral 
cortex, and are least in the hypothalamus (121, 156). Studies using ERα and ERβ knockout mice 
have shown that ERα, but not ERβ, is required for both negative- and positivefeedback regulation 
of gonadotropin-releasing hormone (GnRH) neuron activity by estrogen (26). In contrast, ERβ is 
primarily involved in mood and cognitive activities (28). The functional significance of the dual 
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expression of both ERs within the same hypothalamic area remains unknown; moreover, it is 
possible that a given ER plays different roles in gene regulation (125, 126).    
A specific role for ERα in the control of body weight and food intake also is supported by 
studies with transgenic mice with null mutations affecting estrogen signaling via ERα (69). These 
mice had excess body weight and body fat, as well as decreased energy expenditure, a series of 
effects resembling metabolic syndrome.  In addition, estradiol treatment of these mice, which 
were OVX after puberty, failed to reduce daily food intake, weight gain or fat gain as it did in wild 
type mice (65). Microinjections of low doses of estradiol directly into the brain were shown to 
inhibit food intake (30, 122). Knockdown of VMH ERα results in obesity due to an anabolic process, 
with changes in energy expenditure primarily mediating the weight gain (115).   
Other CNS areas have been investigated. In OVX female rats, c-FOS expression increased 
in the NTS after eating a satiating meal, and in experiments where the amount of food eaten was 
constant for EB- and OIL-treated groups, estrogen increases c-FOS labeling further (50).  However, 
experiments examining c-FOS labeling after treatment with the ‘satiety factor’, cholecystokinin 
(CCK) in EB-treated rats report increases or decreases in c-FOS in the NTS (51, 60).     
A role for the NTS was demonstrated by Thammacharoen and colleagues who showed 
that OVX rats implanted with EB in the hindbrain just caudal to the AP lost body weight (162).  In 
fact food intake in these rats was decreased from control animals during days three and four after 
surgery, a response time consistent with classical ER activation. Taken together, these 
observations suggest that the binding of estradiol to ERα in the hypothalamus, or elsewhere in 
the CNS, may represent a mechanism by which estradiol regulates food intake, body weight, and 




Gastric Mechanisms, Feeding and Body Weight  
 
Because meals end long before substantial digestion and absorption occur (136), gastric 
factors likely serve as satiation signals.  One obvious possibility is gastric distension, and meals do 
end when the stomach is distended (136).  The stomach wall has many stretch receptors, the 
activity of which increases in proportion to the volume in the stomach (136).  Those signals are 
transmitted via the vagus nerve to the NTS and adjacent AP in the brain stem (136), from which  
the information is conducted to the hypothalamus and then to the cortex, where gastric distension 
is then perceived (136).    
Another gastric factor is gastric motility, especially as it relates to prandial periods.    When 
ingested food enters the stomach, the motor pattern changes substantially:  the proximal stomach 
relaxes and initially serves as a reservoir, then by tonic contraction, moves the food distally.  The 
distal stomach in turn mixes and grinds the food by regular and powerful peristaltic contractions.  
In short, the immediate postprandial processes initially allow for large amounts of food to be taken 
in while the proximal stomach is relaxed, generating distension signals that play a major role in 
satiation. The subsequent mechanical aspect of digestion occurs more distally and is followed by 
tonic and peristaltic contractions that allow a controlled flow of food into the duodenum.  
Absorption of nutrients from the duodenum and further along the GI tract also provide ‘satiety’ 
signals.  In the period between meals, proximal stomach muscle tone is high while the distal 
stomach is engaged in a recurrent contraction pattern known as the migrating motor complex 
(MMC), which serves to clear the stomach during fasting between meals (78).  However, extended 
dietary restriction (e.g., 2 hours per day for 4 months) delays gastric emptying in rats; emptying 
returns to normal after three months of free feeding.  However, the mechanism(s) of these 
changes is unknown (143).    
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Little work has focused on estrogen effects on gastric factors.  In experiments including 
ad libitum fed diestrus rats or OVX rats treated with estradiol, estradiol with or without 
progesterone inhibited gastric emptying, while progesterone alone enhanced gastric emptying  
(25). The effect of estrogen to decrease gastric motility may involve increasing CCK secretion and 
CCK receptors on stomach (176).    
  
Hormonal and Peptide Mechanisms, Feeding and Body Weight  
Insulin  
Hormones provide important gluco-regulatory signals to the brain.  After Kennedy (1953) 
hypothesized that fat stores produced a hormone that functioned as a negative feedback control 
for adiposity (84), one early suggestion was that insulin was the hormone involved (13).  Insulin 
increases during meals and other periods of positive energy balance and decreases during fasting 
and other periods of negative energy balance via substrate availability.  During meal anticipation, 
the smell and then the taste of food stimulates insulin secretion.  The process that underlies 
anticipatory insulin release involves input from the forebrain via the hypothalamus to the DMV in 
the caudal brainstem, which is then relayed to the pancreas by way of cholinergic efferent nerves 
of the vagus (116).  This process, along with gastrointestinal signals, insures that the amount of 
insulin secreted is appropriate to efficiently use and store the ingested food.    
Manipulation of gonadal steroid hormone levels can influence CNS sensitivity to insulin 
(30).  This interaction indicates that the relative amounts of androgen and estradiol are key 
determinants of CNS sensitivity to the catabolic actions of insulin:  proportionally less estrogen, 
favors insulin sensitivity (30).   




Meal size and cessation of eating are controlled, at least in part, by hormonal signals from 
the gut such as cholesystokinin (CCK) (10).  CCK, which is secreted during meals in response to 
food, especially lipids, acts on CCK receptors located on vagal afferent fibers that carry gastric 
stretch signals from the pyloric region of the stomach to the brainstem as well as on CCK receptors 
in the AP (137).  Thus, small amounts of CCK can act synergistically with gastric distension to inhibit 
feeding via peripheral and central effects.    
Estrogen potentiates CCK-induced reduction of feeding in ad libitum fed rats (8-10).   
Importantly, at doses of estrogen similar to those used in experiments examining estrogen effects 
on feeding (9, 50, 64), plasma CCK was elevated (176) suggesting that changes in CCK may 
contribute to reduced feeding and therefore body weight in ad libitum fed rats.    
  
Leptin  
Leptin is secreted as an adiposity signal from the peripheral adipose tissue in direct 
proportion to body fat mass. Leptin is detected by CNS receptors located in hypothalamic and 
brainstem areas involved with the control of food intake (154, 174), and at which ER also are found 
(21, 30, 43). This leptin circuit is fairly well defined.  Leptin influences not only food intake, but 
also sympathetic nerve activity via central actions. In food restricted animals, leptin decreases, 
and animals readily eat when food becomes available (92).  Leptin not only suppresses food intake, 
but also enhances energy expenditure to reduce fat depots (171). When male rats were placed on 
a restricted feeding schedule, leptin rhythms were influenced by feeding and reflected levels of 
corticosterone and thyroxine (3). These findings suggest that leptin may have neuroendocrine 
actions secondary to those related to energy homeostasis (2). In agreement with these studies, 
fasting decreased leptin and increased in corticosterone in adult mice (3).    
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The stomach is an additional source of leptin (11, 27, 157) that may influence feeding by 
another mechanism.  Specifically, duodenal infusion of leptin in rats increased plasma CCK to 
levels comparable to those induced by feeding (68), demonstrating that leptin, acts to reduce 
feeding via lumenal leptin receptors (68).  Thus, under physiological conditions, leptin may 
potentiate CCK actions by stimulating its secretion and thereby decrease food intake.    
 Leptin levels are greater in females compared with males, even before puberty, and these levels 
are independent of differences in body adiposity (42, 155).  After puberty, estrogen and 
testosterone further modulate leptin synthesis and secretion via sex steroid receptor-dependent 
transcriptional mechanisms (103). Not surprisingly then, manipulation of gonadal steroid 
hormones can influence sensitivity to leptin and also affect body fat distribution (30).  
  
Ghrelin  
Ghrelin is the only known circulating peptide hormone that stimulates food intake (36).  
In individuals under restricted feeding schedules, ghrelin levels increase approximately 1hr prior 
to food presentation, and this preprandial increase is associated with increased locomotor activity 
in anticipation of a scheduled meal (47).  Ghrelin is synthesized and released primarily by 
endocrine cells in the stomach.  The increases in plasma concentrations of ghrelin before meals 
and rapid decreases after meals, in both humans and rats (38, 164), are consistent with a 
hungerinducing action. Moreover, basal ghrelin levels are decreased in obese humans and 
increased by weight loss (38, 165).   However, a role for ghrelin in control of food intake and body 
weight remains unclear, as plasma ghrelin concentration in humans also increases during the 
evening and decreases in the early morning hours in the absence of eating (38).    
Estrogen decreases the potency of ghrelin, suggesting that weight gain after OVX may be 
ghrelin mediated (31). Specifically, in OVX rats which received peripheral or central doses of 
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ghrelin that did not stimulate eating (31), EB treatment decreased the orexigenic actions of 
ghrelin. Food restriction increases serum ghrelin but decreases both gastric and hypothalamic 
ghrelin in female rats (4).  These findings led investigators to conclude that ghrelin may contribute 
to the suppression of the female reproductive axis during negative energy balance and to propose 
that ghrelin may be a link between body weight homeostasis and reproductive function (4).    
  
Central peptides and neurotransmitters  
  
Neuorpeptide Y (NPY)  
Hypothalamic NPY is an important central regulator of energy homeostasis (29).  It is a 
potent orexigen, increasing feeding behavior in fed and fasted animals (81). Since estrogen acts 
via ERs in the hypothalamus to reduce feeding (169), estrogen’s anorectic effects may be mediated 
by decreasing NPY expression or release (18).  Though it remains unclear whether estrogen 
directly affects NPY neurons, colocalization of ER and NPY immunoreactivity in ARC neurons has 
been reported (152) and estrogen treatment decreased NPY release into the PVN of OVX rats (18).  
  
Melanin-concentrating hormone (MCH)  
MCH has been recognized as an important regulator of energy homeostasis (129) since its 
discovery in hypothalamic neurons (166).  Central administration of MCH promotes feeding and 
the Mch gene is upregulated by fasting (130).  Santollo, et al. observed a greater increase in food 
intake, meal size, and water intake following MCH treatment in male rats than in estradioltreated 
OVX rats.  They also reported that greater MCH doses were necessary to increase food intake in 
estradiol-treated OVX rats (149), leading them to suggest that estradiol reduces MCH sensitivity 





Adrenal steroids suppress growth of experimental animals, inhibit wound healing, cause 
involution of lymphoid tissue, impair bone growth and produce atrophy of skin and subcutaneous 
tissue (reviewed in (55)). In addition, the hormone corticosterone is a potent effector of 
carbohydrate, protein and fat metabolism.  Corticosteroid action on carbohydrate metabolism 
involves increases in gluconeogenesis as demonstrated in adrenalectomized, fasted rats (98). 
Studies of glucose synthesis from 3-carbon precursors provided additional evidence for increased 
gluconeogenesis (95).  It has been postulated that adrenal steroids promote carbohydrate 
synthesis because they stimulate activity of enzymes in the gluconeogenic pathway (110).  
However, rather than being a primary effect of corticosteroids, the alteration of such enzyme 
activity may represent a secondary effect that results from the increased activity in the 
gluconeogenic pathway.  Another potential estrogen effect of increased enzyme activity is 
activation of the type a phosphatase that activates glycogen synthetase (110), increasing glycogen 
deposition.    
The first demonstration of the important influence of corticosteroids on protein 
metabolism came from Long and colleagues in 1940, (98)  but many investigations since have 
shown that adrenal cortical steroids promote protein catabolism and interfere with protein 
synthesis (reviewed in (55)).    Corticosteroids increase levels of free amino acids in muscle and 
reduce capacity of muscle to concentrate amino acids, seemingly due to inhibition of protein 
synthesis (114).  It is generally recognized that muscle is the chief site of protein breakdown and 
source of amino acids following steroid administration.  In contrast, liver amino acid ‘trapping’ is 
stimulated by corticosteroids and the increase in liver protein synthesis resulting from steroids is 
accompanied by an increase in liver tissue RNA content (85).    
14  
  
Inhibition of lipogenesis by adrenal steroids has been observed by many investigators (55, 
101). Although hormonal regulation of lipid mobilization results primarily from controlling the rate 
of triglyceride hydrolysis in adipose tissue by catecholamines, growth hormone (GH) and 
glucocorticoids can act together in vivo to increase fatty acid release from adipose tissue (87).  In 
fact, corticosteroids do not alter lipolysis in adipose in the absence of GH.  In contrast, 
corticosteroids alone exert an important lipolytic action in liver (87).  
In men, estradiol increased cortisol binding protein, but did not increase basal cortisol 
secretion (83).  In post-menopausal women receiving estrogen replacement therapy, free and 
bound cortisol were increased compared to controls receiving progesterone with estrogen (54). 
Subcutaneous injection of estradiol increased corticosterone production in the adrenal zona 
fasciculata-reticularis (ZFR) cells from OVX rats (97).  Increased corticosterone with estrogen may 
involve the hypothalamic-pituitary-adrenal axis.   
  
Metabolic Mechanisms, Food Intake and Body Weight  
All cells of the body depend on continuous supplies of metabolic fuels to support ongoing 
activity. Delivery, storage and mobilization of lipid and carbohydrate metabolites are regulated 
and the control systems involve several hormones as well as the sympathetic and  
parasympathetic nervous systems. Fuels enter the circulation from the small intestine during the 
prandial period and from storage depots during fasting.  The availability of fuels to supply tissues 
is primarily controlled by the liver, the key organ in energy management, and by the hormone 
insulin (173).  Hepatic function and insulin secretion are, in turn controlled by the autonomic 
nervous system. In ad libitum fed rats, lipogenesis (which also occurs in adipose tissue) and 
glycogen formation occur in the liver during the prandial period, and glycogenolysis, ketogenesis 
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and gluconeogenesis occur during the fasting period.  Plasma glucose levels decrease rapidly 
immediately before eating in food restricted rats (96). A single 24 hour fast (or insulin 
administration) produces more rapid depletion of liver glycogen than does chronic food 
restriction.  Glycogen levels are increased or unchanged during food restriction (71), whereas 
lipogenesis in liver and adipose tissue are increased compared to ad libitum fed rats (71, 96).  
  
Carbohydrates and metabolism   
  
Circulating levels of glucose are controlled by two hormones, insulin and glucagon. In 
response to elevated glucose levels, proinsulin is released from pancreatic β cells and converted 
to the active form. When insulin binds to the insulin receptor, a signaling phosphorylation cascade 
starts, which leads to translocation of vesicles containing glucose transporter 4 (GLUT4) to the 
plasma membrane facilitating glucose entry into the cells (179). Insulin, as a result, stimulates the 
uptake and storage of glucose as free fatty acids (FFA) in skeletal muscles and adipose tissue or as 
glycogen through glycogenesis in the liver. Glucagon, on the other hand facilitates glucose-1- 
phosphate release from glycogen polymers, through the action of G-protein receptors on the 
plasma membrane activating glycogen phosphorylase.  
The most important factors influencing glucose short-term fluxes are the hormones 
(insulin, glucagon and catecholamines), the sympathetic nervous system, and the concentration 
of other substrates (FFA).  Long-term control involves other hormones (cortisol and growth 
hormone (GH)), diet composition, physical fitness and changes in the sensitivity to the various 
hormones.  For example, cortisol, GH and catecholamines affect glucose homeostasis by changing 
insulin sensitivity and changing availability of alternate fuels.  While FFA are the main fuel for most 
organs of the body, glucose is the metabolic fuel of choice for the CNS under physiologic 
conditions. However the CNS cannot synthesize glucose or store it as glycogen in amounts 
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sufficient for more than a few minutes supply.  Thus, CNS is dependent on a continuous supply of 
glucose from plasma.    
Carbohydrate catabolism involves glycolysis and Kreb’s cycle, ultimately producing ATP 
through the electron transport system.  Excess glucose from meals, along with glucose produced 
by gluconeogenesis, is stored in the form of glycogen in the liver and catabolically reduced to 
glucose for metabolic fuel during fasting.  When fasting is prolonged, the proportion of glucose 
produced by gluconeogenesis is increased, and contribution of hepatic glycogen stores to the 
glucose pool decreases, while the contribution of the kidney glycogen stores increases (66).  After 
an overnight fast, there is no net storage of glucose and all of the glucose taken in by the tissues 
is completely oxidized (or converted to lactate in the absence of oxygen).  The main regulator of 
insulin secretion is plasma glucose levels; insulin increases several fold after a meal and decreases 
to minimal levels during fasting.   
Glucose exerts vagally-mediated effects upon gastric motility and emptying which in part, 
stabilizes large fluctuations in blood glucose levels following meal ingestion (59, 72, 77, 102, 139). 
An increase in gastric motility in response to hypoglycemia accelerates nutrient delivery to the 
intestine, which allows increased absorption, and thereby re-establishes physiological plasma 
glucose levels (59).  In contrast, decreased gastric motility in response to hyperglycemia delays 
gastric emptying and reduces additional glucose absorption, thereby preventing prolonged, and 
damaging elevations in glucose levels (59).  Protein also regulates blood glucose by stimulating 
insulin and glucagon (147).  In fact oral protein is the most effective macronutrient to modulated 
postprandial glycemia.   
In addition, glucose directly alters the activity of enteric nervous system neurons 
independent of the CNS.  Intra-intestinal infusions of glucose activate sensory neurons in the 
myenteric and submucosal plexuses of the upper small intestine (153, 167).  Glucose also 
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modulates the response of enteric neurons to other GI neurohormones such as CCK and serotonin 
(145). Further, glucose appears to decrease gastric motility and delay gastric emptying via 
paracrine mechanisms. For example, glucose within the lumen of the intestine induces the release 
of neurohormones from enteroendocrine cells, including serotonin from enterochromaffin cells 
within the proximal intestine, and glucagon-like peptide-1 (GLP-1) from L-cells in the distal 
intestine. These neurohormones activate receptors (5-HT3 and GLP-1 receptors, respectively) on 
peripheral vagal afferent nerve terminals and the resulting excitatory signals are transmitted 
centrally (67, 133-135, 138). These sensory signals activate second order neurons within the NTS 
and, after integration, the resulting vagal motor response produces gastric relaxation and delayed 
emptying (59, 138, 180).     
Studies of humans and mice show relationships between estrogen and the regulation of 
glucose homeostasis (90, 104). Estrogen increases glucose uptake in skeletal muscle and adipose 
tissue and decreases gluconeogenesis in liver (58).  Hormone replacement therapy (HRT) has been 
shown to improve insulin sensitivity and to lower blood glucose in healthy postmenopausal 
women and to reduce the incidence of type 2 diabetes in postmenopausal women with coronary 
heart diseases (34, 82). Importantly, men with a deficiency in the enzyme that aromatizes 
testosterone to estrogen and therefore cannot synthesize estrogen, have impaired glucose 
metabolism and increased insulin resistance (112). Female mice with intact ovaries are protected 
against hyperglycemia whereas aromatase knockout mice are insulin resistant (80). ER has been 
shown to be involved in the maintenance of glucose metabolism in several tissues including liver, 
skeletal muscle, adipose tissue, pancreatic β cells, and CNS (7). Estrogens are also known to 
regulate pancreatic β cell function through an ERα-dependent mechanism. One study in mice 
suggests that long-term estrogen exposure increases insulin levels, insulin, gene expression, and 
insulin release, without changing β cell mass (7). Estrogen-dependent insulin release in cultured 
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pancreatic islets was reduced in ERα-deficient mice, when compared with islets derived from 
either ER-deficient or wild type mice (7). However, ERβ-deficient mice show mild pancreatic islet 
hyperplasia with delayed initiation of insulin resistance (12) suggesting that ERβ interrupts 
pancreatic β cell functioning.   
  
Lipids and metabolism   
FFA are the main fuel for most organs of the body and they are released from triglycerides 
by hydrolysis of ester bonds.  In the duodenum, the presence of lipids increases the secretion of 
CCK which causes the release of bile salts from the gall bladder and release of pancreatic lipases 
to further digest lipids.  Short-chain FFA are absorbed via blood capillaries and eventually empty 
into the portal vein where they are transported to the liver and other organs for energy 
production.  Longer-chain FFA, are re-esterified and enter the blood via the lymph vessels as 
chylomicrons.  Triglycerides in chylomicrons are cleared by lipoprotein lipase (LPL) at the capillary 
endothelium and can be stored as fat in adipose tissue.  During fasting elevated glucagon, and 
during exercise, elevated epinephrine, activate hormone-sensitive lipase (HSL) to hydrolyze 
triglycerides to glycerol and FFA.  The FFA then are used as fuel in most tissues, except the CNS.  
During fasting or exercise LPL, fatty acid synthesis and triglyceride synthesis are inhibited.  In the 
fed state, insulin inhibits HSL and no FFA are released from adipose tissue.  Insulin also stimulates 
glycolysis and inhibits gluconeogenesis in the liver as well as stimulating fatty acid and triglyceride 
synthesis in the liver.    
The role of specific fatty acids and lipids in body weight control focuses on their utility in 
promoting satiety with respect to energy intake, body composition, energy expenditure, fat 
oxidation and energy efficiency.  The presence of food, particularly fat (20), or leptin (68) in the 
upper small intestine stimulates release of CCK, which has regulatory roles in bile secretion, gastric 
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emptying and exocrine pancreas activity, in addition to vagally-mediated effects to inhibit eating 
and terminate meals (41).  
The delaying effect of lipid on gastric emptying is increased in the elderly, and the 
administration of lipase accelerates the emptying of lipid from the stomach (117). In men, it is 
possible to delay gastric emptying and increase satiety using fat emulsions that have been 
stabilized against the acidic gastric environment (106). In lean men, it has been shown that lipid 
placed intraduodenally modulated gastrointestinal motility and hormone release and suppressed 
energy intake more than did glucose placed intraduodenally. Despite differing effects on gut 
function, both lipid and protein in the duodenum produced (44) comparable reductions in energy 
intake.   
Adipose tissue and liver are the most important tissues for the influence of EB on lipid 
metabolism.  Estrogens influence adipose tissue cells and liver cells by endocrine and paracrine 
mechanisms and are also produced in these cells from androgens found there. Moreover, 
estrogen can be stored as esters with long-chain fatty acids in adipocytes (161).  ERs are present 
in adipocytes (44, 161) and hepatocytes (161),  but their density is much lower than that in gonads. 
On the cellular level, estrogens regulate mRNA production for particular proteins, among which 
are the proteins involved in lipid metabolism. In adipose tissue, EB has a direct effect on LPL and 
HSL (161). Specifically, LPL synthesis is more rapid, while the synthesis of HSL is delayed in the 
presence of estrogen. Finally, indirect action of estrogens on adipose tissue is connected with the 
release of other hormones which increase HSL activity, including catecholamines, GH and 
glucagon (161).  
Clearly, estrogen levels in reproductively intact females are high enough to change lipid 
metabolism.  Accumulation of adipose tissue is sexually dimorphic (140) with females having a 
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higher percentage of body fat than males. Fat distribution is also different with females 
accumulating more subcutaneous fat and males accumulating more visceral fat (19) (34) (118). 
Estrogen deficiency or the decline in estrogen levels after menopause can cause dysregulation of 
metabolism. The onset of menopause is associated with several metabolic changes and 
postmenopausal women fall into the same risk category as men for development of  
atherosclerosis and myocardial infarction (23). Other changes associated with low estrogen levels 
are insulin resistance, impaired glucose metabolism, increased hepatic gluconeogenesis with 
subsequent glucose secretion, and increased levels of inflammatory markers (58).   
Finally, Clegg et al. (30) report that estrogen regulates body fat distribution, interacts with 
the adiposity signal leptin, and enhances leptin’s central action to alter sympathetic outflow to 
the visceral fat. This sympathetic action facilitates fat mobilization in the visceral depot and fat 
deposition in the subcutaneous depot.  Estrogen regulates body adiposity and fat distribution 
through its receptors ERα and ERβ (91). However only ERα has been reported to have a major 
influence on energy homeostasis (69).  Heine et al. (69) reported that male and female mice with 
total body deletion of ERα, have increased adiposity in both male and female mice, suggesting an 
important role for this estrogen receptor in the regulation of body weight and adiposity.   
  
  
Targeted Temporal Food Restriction (TTFR)  
 
Much of the advances in understanding integrated physiological, hormonal, metabolic 
and central control of food intake and body weight, and EB effects on these processes, are the 
result of studies conducted during ad libitum feeding conditions.  However, many obese people 
restrict their eating and consume most of their food during the evening, when activity is less, 
eating little or no breakfast or lunch (14, 46, 63).  Substantial alterations to integrated control 
processes for feeding and body weight may occur during TTFR.  
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TTFR was used to examine changes in metabolism and the regulating hormones in male 
rats that were given more food than they could consume in the two hour period allowed for eating 
(70).  These rats lost about twenty percent of their starting weight within the first few days which 
then increased gradually to return to the starting weight over the next three weeks.  Food 
consumption in the two hour period also increased during TTFR, ultimately returning to 95 percent 
of the food consumed during the ad libitum period.  Importantly, the large load of nutrients taken 
in during TTFR was not stored as glycogen, but entered the system as newly synthesized lipids.  
This effect was proposed to be due to adaptation to the feeding program, such that male rats 
metabolized fat as their major energy source and limited glucose utilization to the small amounts 
required by the central nervous system (70).  Lima, et al (96) also employed TTFR in male rats but 
gave 2 hours of access to chow either in the morning or at night.  In these studies, food intake did 
not increase to levels approximating those during ad libitum conditions with day or nighttime 
feeding, nor did body weight increase during the experiment. In addition, their results showed 
that when food availability was restricted to short periods of time as with TTFR gastric emptying 
is much slower than in ad libitum feeding conditions.  Lima and colleagues also proposed an 
adaptive hypertrophy in gastric mucosa during TTFR that allows increased absorption. Based on 
these experiments, rats allowed to eat for only a short period each day, as with TTFR, may have 
more efficient nutrient uptake and utilization (32).  With prolonged TTFR, changes in gastric 
function occur along with metabolic changes that increase lipogenesis in liver and fatty tissue (94) 
and decrease hepatic glycogen depletion (93).    
Female rats have been subjected to TTFR in various feeding protocols (feeding for 2-4 hr 
one or more times per day) (123, 128, 160, 163).  These studies focused on the effects on 
lipogenesis in brown adipose tissue, glycogen and glucose synchronization to the phases of the 
circadian cycle during TTFR, and the advantage of TTFR-induced diminished insulin release in the 
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progression of breast tumors.  However, estrogen effects on the CNS or metabolic factors that 
affect body weight and food intake during TTFR have not been investigated in the female rat.    
In this dissertation research, I use OVX rats to model the restricted eating schedule of 
some obese people, who eat little breakfast and lunch but eat most calories in the evening at the 
low energy time of day, by giving the rats food access two hours during the day when their activity 
is less (i.e. a TTFR protocol).  My goal is to study estrogen’s effects on the signals that control 
eating and body weight during TTFR. To accomplish this goal, I have compared OVX rats with and 
without estrogen treatment during TTFR.  I first assessed food intake and body weight during TTFR.  
Next, I investigated central mechanisms of estrogen effects during TTFR by examining neural 
interactions in the hindbrain NTS, where vagal afferents from the gastrointestinal tract terminate.  
Next, I investigated peripheral mechanisms underlying estrogen effects during TTFR, by assessing 
carbohydrate and fat metabolism, and related hormones.  Better understanding of the influence 
of estrogen on these factors may have critical implications for understanding the effectiveness of 
food restriction for weight loss (i.e. dieting) and, perhaps, for success in maintaining body weight 

















CHAPTER III  
  
  
MATERIALS AND METHODS  
  
Animals, Surgeries and Hormone Treatments  
Adult female Sprague-Dawley rats (Charles River), three months of age, were housed in 
individual cages in a temperature controlled (22 ± 2° C) room on a 12:12 light:dark cycle (lights on 
0700). All rats were given ad libitum access to water and chow (Harlan rodent diet #2018) except 
as described. Experimental protocols were in accordance with the National Institutes of Health  
Guide for the Care and Use of Laboratory Animals and all procedures were approved by the 
Oklahoma State University Center for Health Sciences Institutional Animal Care and Use 
Committee. After one week to acclimate to the colony room rats, were bilaterally OVX by a 
midventral incision under pentobarbital anesthesia (50 mg/kg i.p.; Sigma-Aldrich) and allowed to 
recover for 7-10 days. After recovery, a regimen of 0.1 ml subcutaneous injections with 17-
βestradiol-3-benzoate (EB; 10 μg/0.1 ml sesame oil; Fisher Scientific), or sesame oil vehicle (OIL; 
0.1 ml) was initiated, with injections given on two consecutive days at weekly intervals for the 
duration of the experiment. The experimental protocol is shown schematically in Figure 1.  
  
Figure 1:  Schedule of EB/OIL injections and experimental protocol.  
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Feeding Protocol  
Rats were weighed each day at 10:00, and chow and water then were removed from the 
cages. Pre-measured chow was returned to the cages from 13:00 to 15:00, along with water in 
graduated cylinders fitted with sipper tubes. Water intake was measured after two hours and 
uneaten chow was collected and weighed to determine intake during this targeted 2-hour intake 
period.    
For the first two weeks (Week 1 and Week 2), pre-weighed chow and water were returned 
at 15:00. Rats had ad libitum access to chow and water overnight and intakes of both were 
determined the following morning. After this two week period to adapt to the targeted 2-hour 
intake period, the overnight feeding was discontinued. During the next week (Week 3), access to 
chow was restricted to the targeted 2-hour period each day (13:00 to 15:00), temporally targeted 
food restriction (TTFR), though rats continued to have ad libitum access to water each night.   
Rats were euthanized 48 hours after the second OIL or EB injection on Week 3. On the day 
of euthanization, some food restricted OVX rats were permitted to eat for 1 hour (FED) and then 
euthanized one hour later; chow intake during this 1-hour intake test was measured. To control 
for non-specific effects of TTFR, other food restricted OVX rats were not permitted to eat (FASTED) 
prior to euthanization on Week 3. Separate groups of OVX rats were maintained on ad libitum 
access to chow until they were euthanized on Week 3 and, thus, served as untreated controls.  
  
CNS IMMUNOLABELING  
  




On the day of euthanization on Week 3, rats were deeply anesthetized with pentobarbital 
(25 mg/rat, i.p.) and then perfused transcardially with 0.15 M NaCl (~300 ml) followed by 
phosphate buffered 4% paraformaldehyde (~300 ml). Brains were removed, stored in 
paraformaldehyde overnight at 4° C, and then transferred to 30% sucrose for cryoprotection. 
Brains were stored at 4° C, until cut into 40-µm sections in a 1-to-3 series using a cryostat (Leica). 
Sections were stored at -20° C in a cryoprotectant solution (1% polyvinylpyrrolidone, 30% ethylene 
glycol, 30% sucrose in sodium phosphate; pH 7.2), until processed for ERα or fos immunolabeling.   
 
ERα Immunohistochemistry and Quantification  
 
One series of free-floating hindbrain (NTS) sections was rinsed of cryoprotectant by six 
5minute washes with 0.05 M Tris NaCl and then incubated in 0.5% H2O2 in 0.05 M Tris NaCl for 30 
minutes at room temperature. After six 5-minute washes with 0.05 M Tris NaCl, sections were 
incubated in 10% normal goat serum (NGS; mixed in 0.5% Triton-X with 0.05 M Tris NaCl) for 1 
hour at room temperature. Sections were then transferred to the primary antibody (Millipore, 
rabbit anti-ERα) diluted 1:10,000 in 2% NGS for one hour at room temperature, followed by 70 
hour incubation at 4° C.   
Sections were brought to room temperature, rinsed three times for 5 minutes each with 2% 
NGS and then  incubated for ~4 hours in the secondary antibody, (Jackson Immunoresearch goat 
anti-rabbit IgG - Cy2) diluted 1:300 in 2% NGS. Sections then were rinsed two times with 2% 
NGS, followed by three rinses with 0.05 M Tris NaCl.  
Labeled sections were ordered and mounted on gelatin coated slides and allowed to dry. 
Sections were dehydrated on the slides in an ascending series of ethanols (70%, 90% and 100%), 
defatted in xylenes, and coverslips then were attached with Cytoseal (Thermo Scientific). Slides 
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were examined at 10X magnification with a Nikon Eclipse 80i microscope fitted with FITC and 
rhodamine filters and NIS Elements software.   Sections containing the NTS were identified using 
the atlas of Paxinos and Watson (124). The NTS was outlined caudal to calamus scriptorius (cNTS;  
-14.30 to -14.60 mm relative to Bregma); and at the middle level subadjacent to the area postrema 
(midNTS; -13.68 to -14.08 mm relative to Bregma).  ERα-labeled neurons were counted in 2-4 
sections at each level that were matched between animals. Average numbers of ERlabeled cells 
were calculated for each animal at each level and group means for each level were determined 
for each feeding condition.  
  
Fos Immunolabeling and Quantification  
 
Another series of free-floating hindbrain sections were rinsed of cryoprotectant, incubated 
in 0.5% H2O2, washed with 0.05 M Tris NaCl, and incubated in 10% NGS (mixed in 0.5% Tween 20 
with 0.05 M Tris NaCl). Sections then were transferred to the primary antibody (Santa Cruz SC-52, 
rabbit anti-c-Fos) diluted 1:30,000 in 2% NGS and incubated at room temperature for one hour 
before overnight incubation (~18 hr) at 4° C.    
The following morning, sections were brought to room temperature, rinsed three times for 5 
minutes with 2% NGS and then incubated for two hours in the secondary antibody (Vector 
biotinylated goat anti-rabbit IgG) diluted 1:300 in 2% NGS. Sections then were rinsed two times 
with 2% NGS, followed by three rinses with 0.05 M Tris NaCl. Labeling was amplified with 
avidinbiotin (Vector, Vectastain ABC kit) for 90 minutes and sections then were rinsed. Labeling 
was visualized with nickel-intensified diaminobenzidine (Vector DAB kit) to produce a blue-black 
nuclear reaction product. The reaction was terminated by multiple rinses with 0.05 M Tris NaCl.  
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Labeled sections were ordered and mounted on gelatin coated slides, allowed to dry and then 
dehydrated and defatted as described.  Coverslips then were attached and slides were examined 
using a Nikon Eclipse 80i microscope.  Sections containing the cNTS and midNTS were identified 
and outlined as described.  Fos-positive nuclei within the cNTS and midNTS were quantified in 2-
3 representative sections from each area, matched between animals. Average numbers of fos-
positive nuclei were calculated for the cNTS and for the midNTS for each animal; group means 
then were determined for each feeding condition.    
  
PERIPHERAL METABOLIC FACTORS  
  
Peripheral Tissue Harvesting:  
Rats that were used to examine peripheral tissues were euthanized with CO2 and 
decapitated.  Trunk blood was collected into Lithium EDTA tubes and centrifuged to obtain plasma 
which was then frozen in aliquots for later analysis of hormones and fat and carbohydrate 
metabolites. Uterus, retroperitoneal fat and adrenals were collected and weighed.  Abdominal fat 
and liver samples were collected and quick frozen for further analysis.  
Stomachs were removed, blotted and weighed with contents intact to the nearest 0.1 
gram.  Then they were sliced open from esophageal to pyloric sphincter, contents were removed 
and the stomachs were rinsed with saline, blotted and weighed again.  Differences in weights were 




Plasma Hormone Analysis:  
Leptin, insulin, and corticosterone were measured by ELISA according to the 
manufacturer’s instructions. The Millipore leptin assay is a sandwich ELISA based, sequentially, 
on: 1) binding of leptin in the sample by a pre-titered antiserum and immobilization of the 
resulting complexes in the wells of a microtiter plate, 2) after washing purified biotinylated 
detection antibody is allowed to bind to the immobilized leptin, 3) binding of horseradish 
peroxidase to the immobilized biotinylated antibodies after free detection antibodies are washed 
off, 4) wash away of free enzyme conjugates, and 5) quantification of immobilized antibody- 
enzyme conjugates by monitoring horseradish peroxidase activities in the presence of the 
substrate 3,3’,5,5’-tetramethylbenzidine (TMB).  The enzyme activity is measured 
spectrophotometrically by the increased absorbency at 450 nm, corrected from the absorbency 
at 590nm, after acidification of formed products.  Since the increase in absorbency is directly 
proportional to the amount of captured leptin in the unknown sample, the latter can be derived 
by interpolation from a reference curve generated in the same assay with reference standards of 
known concentrations of rat leptin.    
The Millipore insulin assay is also a sandwich ELISA based sequentially, on: 1) capture of 
insulin molecules from samples to the wells of a microtiter plate coated by pre-titered amount of 
a monoclonal mouse anti-rat insulin antibodies and the binding of biotinylated polyclonal 
antibodies to the captured insulin, 2) wash away of unbound materials from samples, 3) binding 
of horseradish peroxidase to the immobilized biotinylated antibodies, 4) wash away of free 
enzyme conjugates, and 5) quantification of immobilized antibody-enzyme conjugates by 
monitoring horseradish peroxidase activities in the presence of the substrate TMB.  The enzyme 
activity is measured spectrophotometrically by the increased absorbency at 450 nm, corrected 
from the absorbency at 590nm, after acidification of formed products.  Since the increase in 
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absorbency is directly proportional to the amount of captured insulin in the unknown sample, the 
latter can be derived by interpolation from a reference curve generated in the same assay with 
reference standards of known concentrations of rat insulin.    
 The Enzo corticosterone kit is an ELISA assay.  The kit uses a polyclonal antibody to corticosterone 
to bind, in a competitive manner, corticosterone in the standard or sample or an alkaline 
phosphatase molecule which has corticosterone covalently attached to it.  After a simultaneous 
incubation at room temperature the excess reagents are washed away and substrate is added.  
After a short incubation time the enzyme reaction is stopped and the yellow color generated is 
read on a microplate reader at 405 nm.  The intensity of the bound yellow color is inversely 
proportional to the concentration of corticosterone in either standards or samples.  The measured 
optical density is used to calculate the concentration of corticosterone.   Plasma samples were 
diluted sixty-fold with assay buffer before assay.  
Plasma Metabolite Analysis (colorimetric):  
Glucose, glycogen, free fatty acids (FFA) and triglycerides (TG) were measured with 
colorimetric kits with the appropriate blanks according to the manufacturer’s instructions.  
 The BioVision glucose colorimetric assay was used to directly measure glucose in one microliter 
of the plasma samples undiluted.  The assay was done in 96-well microtiter plates and read on the 
microplate reader.  Glucose enzyme mix provided, oxidizes glucose specifically, to generate a 
product with reacts with a dye to generate color at 570 nm.  The generated color is directly 
proportional to the amount of glucose present and the sample concentrations are read from the 
standard curve prepared.  
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In the Abcam assay, glycogen is hydrolyzed into glucose, which is oxidized to form an 
intermediate that reduces a colorless probe to a colored product with strong absorbance at 450 
nm. This assay kit can detect less than 4 µg/ml of glycogen in samples.   
FFA were measured using the Cayman Chemical company fluorimetric assay kit in 96-well 
microtiter plates.  The assay utilizes a coupled enzymatic reaction to determine FFA 
concentrations.  Acyl CoA synthetase (ACS) first catalyzes fatty acid acylation of coenzyme A.  The 
acyl CoA produced is oxidized by acyl CoA oxidase (ACOD) and generates hydrogen peroxide.  
Finally, the hydrogen peroxide, in the presence of horseradish peroxidase, reacts with 10-aceyl3,7-
dihydroxyphenooxazine (ADHP) in a 1:1 stoichiometry to generate the highly fluorescent product 
resorufin.  Resorufin fluorescence was measured with an excitation wavelength between 530-540 
nm and and emission wavelength between 585-595 nm.  The plasma sample concentrations were 
determined using a standard curve.  
In the Abcam assay, TG are converted to free fatty acids and glycerol. The glycerol is then 
oxidized to generate a product which reacts with the probe to generate color (spectrophotometry 
at λ = 570 nm).  The kit can detect 2 pmol-10 nmol (or 2-10000 pM range) of triglyceride in various 
samples. The kit also detects monoglycerides and diglycerides.  
  
Liver and Abdominal Adipose Triglycerides:  
Frozen liver or adipose tissue was placed into 2 ml microcentrifuge tubes, subsequently 
weighed and homogenized at 5mg/ml in 4% NP 40 using multiple bursts of a sonic homogenizer 
(set at 3) on ice. The homogenates were centrifuged in the microfuge at 14000 x g for 5 minutes 
at 4 degrees C.  The supernatants were then diluted ten-fold in deionized water and frozen at -20 
degrees C until analysis in the colorimetric kit the following day. In the colorimetric Abcam assay, 
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TG are converted to free fatty acids and glycerol. The glycerol is then oxidized to generate a 
product which reacts with the probe to generate color (spectrophotometry at λ = 570 nm).  The 
kit can detect 2 pmol-10 nmol (or 2-10000 pM range) of triglyceride in various samples. The kit 
also detects monoglycerides and diglycerides.  
Liver Glycogen:  
Frozen liver was placed into 2 ml microcentrifuge tubes, subsequently weighed and 
homogenized at 5 mg/ml in the glycogen assay buffer from the analysis kit using multiple bursts 
of a sonic homogenizer (set at 3) on ice.  The homogenates were centrifuged in the microfuge at 
14000 x g for 5 minutes at 4 degrees C.  The supernatants were then analyzed directly in the 
colorimetric kit the same day. In the Abcam assay, glycogen is hydrolyzed into glucose, which is 
oxidized to form an intermediate that reduces a colorless probe to a colored product with strong 
absorbance at 450 nm. This assay kit can detect less than 4 µg/ml of glycogen in samples.  
    
STATISTICS  
All data are presented as means ± standard error of the means.   
Change in body weight during ad libitum conditions was analyzed using two-way ANOVA with 
hormone (OIL, EB) and Week (1,2,3) as factors.  Change in body weight during Week 3 using 
twoway ANOVA with hormone (OIL, EB) and day (1,2,3) as factors.  Food intake on day 4 was 
analyzed by two-way ANOVA with hormone (OIL, EB) and feeding condition (ad lib, FED). Pair-wise 
comparisons of significant main effects or interactions were evaluated using Fisher’s LSD test.   




Numbers of ER in the NTS and numbers of fos positive nuclei in the cNTS and midNTS were 
analyzed using separate two-way ANOVAs with hormone (OIL, EB) and feeding condition (ad lib, 
fasted, fed) as factors. Pair-wise comparisons of significant main effects or interactions were 
evaluated using Fisher’s LSD test. Additional planned comparisons of specific groups were made 
using Bonferroni corrections.  
Metabolite and hormone data were analyzed by two-way ANOVA with hormone (OIL, EB) 
and feeding condition (ad libitum, FED, FASTED) as factors.  Stomach and adrenal weights were 
analyzed by two-way ANOVA with hormone (OIL, EB) and feeding condition (ad lib, FED, FASTED) 
as factors.  










As shown in Figure 2, two-way ANOVA revealed that uterine weights were affected by hormone 
(F(1,28) = 166.06, p<0.001) and were less in OIL treated rats.  There was no effect of feeding 
condition and no interaction between hormone and feeding condition.   
 
Figure 2:  Uterine weights as an indication of estrogen effectiveness. Ovariectomized rats were 
given subcutaneous injections of 17-β-estradiol-3-benzoate (EB; 10 μg/0.1 ml sesame oil) or the 
sesame oil vehicle (OIL; 0.1 ml) twice weekly for three weeks.  Blue bars denote ad libitum fed 
rats (ad lib; OIL – n=5, EB – n= 6); gray bars denote TTFR rats that were fasted on the test day 
(fasted; OIL – n= 6, EB – n=6); orange bars denote TTFR rats that were fed on the test day (fed; 


















Change in body weight during ad libitum condition is shown in Figure 3.  Two-way ANOVA 
revealed that change in body weight was affected by hormone treatment (F(1,77) = 87.63, p<0.001) 
with EB-treated rats exhibiting body weight loss compared to the weight gain exhibited by 
OILtreated rats.  There was no effect of week, nor interaction between hormone and week.  
 
Figure 3:  Change in body weight after EB injections twice weekly over three weeks of ad lib 
feeding is a reliable indicator of EB-treatment.  OIL: week 1 n=18, week 2 n=18, week 3 n=6; EB: 
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Figure 4 shows daily body weight during weeks 1-3 in rats fed ad libitum throughout (Figure  
4a) and in rats in the TTFR condition during week 3 (Figure 4b).    
 
Figure 4a:  Body weights of ad libitum fed rats over the three weeks of the experiment.  Blue 
filled circles denote OIL treated rats and orange filled circles denote EB-treated rats. OIL, n=5; 
EB, n=6.    
  
 
Figure 4b:  Body weights of rats that underwent TTFR on week 3, over the three weeks of the 
experiment.  Blue filled circles denote OIL treated rats and orange filled circles denote EBtreated 
rats.  OIL, n=12; EB, n=12  
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 Figure 5 shows the change in body weight each day during week 3.  Two-way ANOVA 
revealed a main effect of day (F(2,66) = 21.88, p<0.001) and pairwise comparisons showed that, 
independent of hormone, loss on day 1 was significantly greater than that on both day 2 and day 
3 (ps<0.001).  Weight loss on day 2 was significantly greater than that on day 3 (p<0.01).  There 
was also a main effect of hormone (F(1,66) = 6.00, p<0.05) with EB-treated rats exhibiting greater 




Figure 5:  Daily change in body weight during week 3.  * = significantly more body weight loss on 

























Food intake on day 4 of week 3 (the day of euthanization), is shown in Figure 6.  There was a 
main effect of feeding condition (F(1,17) = 58.62, p<0.001), with food intake by the fed group greater 
than that by the ad lib group, independent of hormone.  There was no effect of hormone nor 
between hormone and feeding condition.  
 
Figure 6: Food intake on day 4 of week 3 TTFR.  * = significantly greater than ad lib fed rats.  OIL: 
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The weight of stomach contents in the various feeding conditions is shown in Figure 7.  
Twoway ANOVA revealed a main effect of feeding condition (F(2,30) = 52.62, p<0.001).  Pairwise 
comparisons showed that, regardless of hormone, stomach contents were significantly greater in 
the fed groups than in both the ad lib group (which was greater) and fasted group (ps<0.001).  
  
    
 
Figure 7:  Weight of stomach contents on day 4 of week 3.  * = significantly more than ad lib and 


























Figure 8 shows quantification of ERα in NTS.  Neither feeding condition, hormone treatment, 
nor the interaction altered numbers of ERα in the midNTS (Figure 8a).  Similarly, ERα numbers in 
the cNTS were not affected by hormone, feeding condition nor the interaction (8b).   
Representative digital photomicrographs are shown in Figure 8c.  
 

























Figure 8:  ERα quantification in the nucleus of the solitary tract (NTS).  8a shows the midNTS 
(OIL: ad lib n=5, fasted n=3; EB: ad lib n=3, fasted n=4) and 8b shows the cNTS (OIL: ad lib n=5, 
fasted n=3; EB: ad lib n=3, fasted n=4).  
  
Figure 8c.  Representative digital photomicrographs of ERα immunohistochemistry in the 









Figures 9a and 9b shows quantitification of fos immunolabeling in the NTS. In both the mid 
(Figure 9a) and cNTS (Figure 9b), few nuclei were labeled for fos in the ad lib groups, which ate 
little or nothing (0-0.14 g) in the 1-hour time period prior to euthanization, or in the TTFR groups 
that were fasted prior to euthanization (fast). In contrast, fos immunolabeling was elevated in the  
NTS of the TTFR rats that were allowed to eat for 1 hour prior to euthanization (fed). Two-way 
ANOVAs revealed significant main effects of feeding condition in both the midNTS (F(2,24) = 17.80, 
p<0.001) and cNTS (F(2,24) = 6.93, p<0.01). Pairwise comparisons showed that, regardless of 
hormone treatment, numbers of fos-positive nuclei in both midNTS and cNTS were significantly 
greater in the fed groups than in the ad lib and fasted groups (p<0.001), which were not different 
from each other. There was no effect of hormone on numbers of fos-positive nuclei in either the 
midNTS or cNTS, and no interactions between hormone and feeding condition. Representative 













Figure 9:  cFOS quantification in the NTS.  9a shows midNTS (OIL: ad lib n=5, fasted n=3, fed n=7; 
EB: ad lib n=4, fasted n=4, fed n=8) and 9b shows cNTS (OIL: ad lib n=5, fasted n=3, fed n=7; EB: 
ad lib n=4, fasted n=4, fed n=7).  * = significantly greater than either the ad lib or fasted groups 
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Figure 9c.  Representative digital photomicrographs of c-Fos immunohistochemical labeling in 










Plasma insulin levels are shown in Figure 10.  Two-way ANOVA demonstrated a main 
effect of feeding condition (F(2,28) = 11.64, p<0.001), with pairwise comparisons showing that 
levels of insulin in the fasted group were significantly less compared to both ad lib and fed 
groups (ps<0.001). No hormone effect nor interaction between hormone and feeding group was  




Figure 10:  Plasma insulin measured on day 4 of week 3. * = significantly less than the ad lib or 




















  Plasma glucose levels are shown in Figure 11.  Two-way ANOVA revealed a main effect 
of hormone on plasma glucose concentration (F(1,30) = 14.22, p<0.001,) with glucose levels in 
EBtreated rats significantly  less than those in OIL-treated  rats, independent of feeding 
condition. There was no effect of feeding condition, nor was there an interaction between 
hormone and feeding condition.  
 
Figure 11:  Plasma glucose measured on day 4 of week 3. * = significantly less than OIL-treated 





















Liver glycogen levels are shown in Figure 12.  Two-way ANOVA revealed a main effect of 
feeding condition (F(2,18) = 56.03, p<0.001) and pairwise comparisons showed that, independent 
of hormone, liver glycogen was significantly greater in the ad lib compared to that in both fed 
and fasted groups (p<0.001).  In addition liver glycogen was greater in the fed group than in the 
fasted group (p<0.01).  No hormone effect or interaction was shown.  
 
Figure 12:  Liver glycogen measured on day 4 of week 3. **significantly greater than fasted and 
fed groups; * = significantly greater than fasted group.  OIL: ad lib n=4, fasted n=2, fed n=5; EB:  





















 Leptin values are shown in Figure 13.  Two-way ANOVA revealed a main effect of 
feeding condition (F(2,28) = 7.92, p<0.01) with pairwise comparisons showing that ad lib group had 
significantly greater leptin levels than did fasted and fed groups (ps<0.001).  In addition, leptin 
levels in the fed group were significantly greater than those in the fasted group (p<0.05).   
There was no hormone effect or interaction.  
 
Figure 13:  Plasma leptin measured on day 4 of week 3. ** = significantly greater than fasted 
and fed groups; * = significantly greater than fasted group.  OIL: ad lib n=6, fasted n=5, fed n=6; 






















  Plasma triglycerides are shown in Figure 14.  Two-way ANOVA revealed a main effect of 
hormone (F(1,29) = 18.89, p<0.001) with plasma triglycerides in EB-treated rats significantly 
greater than those in OIL-treated rats.  There also was a main effect of feeding condition (F(2,29) = 
16.11, p<0.001) and pairwise comparisons showed that plasma triglycerides in the fasted group 
were significantly less than those in ad lib and fed groups (ps<0.001) which were not different 
from each other. There was no interaction between hormone and feeding condition.  
 
Figure 14:  Plasma triglycerides measured on day 4 of week 3. ** =significantly greater than 
OIL-treated rats; * = significantly less than the ad lib and the fed group.  OIL: ad lib n=6, fasted 

























The quantification of plasma FFA is shown in Figure 15a.  Two-way ANOVA revealed a 
main effect of hormone (F(1,30) = 10.15, p<0.01) with plasma FFA in EB-treated rats significantly 
greater than those in OIL-treated. There also was a main effect of feeding condition (F(2,30) = 9.35, 
p<0.001), and pairwise comparisons showed that the fasting group was greater than the fed 
group (p<0.001) and greater than the ad lib group (p<0.05).  
 
Figure 15a:  Plasma free fatty acids (FFA) measured on day 4 of week 3. ** = significantly 
greater than OIL-treated controls. * = significantly greater than ad lib and fed groups. OIL:  ad lib 























Percent change in FFA is shown in Figure 15b.  Two-way ANOVA revealed a main effect 
of feeding condition (F(1,20) = 17.39, p<0.001) and pairwise comparisons of feeding condition 
showed greater percent change in fasted animals.  A main effect of hormone was also seen 
(F(1,20) = 9.85, p<0.01), with a greater percent change in OIL-treated animals.  No interaction 
between feeding condition and hormone was seen.  
 
Figure 15b:  Percent change from ad lib in plasma FFA measured on day 4 of week 3. * = 



























 Adipose triglyceride levels are shown in Figure 16.  Two-way ANOVA revealed no main 
effects or interactions.  
 
Figure 16:  Adipose triglycerides measured on day 4 of week 3. OIL:  ad lib n=4, fasted n=6, fed 























Adrenal weights are shown in Figure 17.  Two-way ANOVA revealed a main effect of 
hormone (F(1,27) = 18.09, p<0.001), with EB-treated animals having greater adrenal weights than 
did OIL-treated controls.  There were also was a main effect of feeding condition (F(2,27) = 13.01, 
p<0.001) and pairwise comparisons revealed that adrenal weights in the ad lib group were 
significantly less (p<0.001) than in fed and fasted groups, which were not different from each 




Figure 17:  Adrenal weights measured on day 4 of week 3.  * = significantly greater than 
OILtreated controls.  OIL:  ad lib n=6, fasted n=5, fed n=5; EB:  ad lib n=6, fasted n=6, fed n=5.  
  
















 Plasma corticosterone levels are shown in Figure 18.  Two-way ANOVA revealed main 
effects of feeding condition (F(2,22) = 15.05, p<0.001), hormone (F(1,22) = 56.91, p<0.001) and an 
interaction between feeding condition and hormone (F(2,22) = 10.02, p<0.001).  Pairwise 
comparisons of the interaction revealed no differences in the corticosterone levels in the two  
ad lib groups, but in fasted groups and fed groups plasma corticosterone in EB-treated rats was 
greater than that in OIL-treated rats (ps<0.001).  Plasma corticosterone of EB-treated ad lib 
group was less (ps>0.001) than that of fasted and fed groups, while plasma corticosterone of the 
fasted group was greater than that of the fed group (p<0.05) in the EB-treated rats.  There were 
no differences in the OIL-treated groups between feeding conditions.  
 
Figure 18:  Plasma Corticosterone measured on day 4 of week 3.  a=significantly greater than  
OIL fasted, b=significantly greater than OIL fed, 1=significantly greater than EB ad lib, 
2=significantly greater than EB fasted.  OIL:  ad lib n=4, fasted n=5, fed n=5; EB:  ad lib n=6, 
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Table 1.  Summary of Results Affected by EB treatment  
Decreased by EB treatment  Increased by EB treatment  
Plasma glucose (overall)  Plasma Triglycerides (overall)  
  Plasma Free Fatty Acids (overall)  
  TTFR Fasted plasma Free Fatty Acids  
  Adrenal Weights (overall)  
  TTFR Fasted plasma Corticosterone  





























Over the last 40 years, the role of estrogens in feeding and body weight regulation has 
become the subject of intensive investigation. From seminal observations of feeding behaviors in 
rats by Wade and colleagues in the mid-1970s (17, 52, 168) to more recent studies employing 
sophisticated techniques to explore the molecular bases of the actions of estrogens in the control 
of ingestive behaviors (115), work in this area has led to better understanding of the control of 
feeding and body weight during ad libitum feeding conditions. Indeed, investigators are beginning 
to dissect out specific CNS areas, neurotransmitter systems, and estrogen receptor subtypes (53, 
73, 142, 149-151), that will allow manipulations for even more finely-honed approaches to 
understanding the mechanism(s) of the actions of estrogens, especially as it pertains to the CNS. 
Certainly, there are conflicting findings about the location of central estrogen receptors that 
control feeding and body weight (73, 151), and the relative influence of specific central 
neurotransmitter systems remains to be determined (53, 142, 148-150). Nonetheless, remarkable 
progress has occurred, particularly in regard to the control of feeding during conditions of ad 
libitum access.    
To my knowledge, this is the first comprehensive investigation focused on the influence 
of estrogen on chow intake and body weight of OVX rats during TTFR. Given the propensity of 
overweight and obese individuals to eat only one large meal at the end of the day, when energy 
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levels are low (14, 46, 159), and the fact that females suffer disproportionately from obesity, the   
goals of this study, therefore, were to examine the effects of estradiol during TTFR and to test 
CNS and peripheral mechanisms that may underlie these effects. Better understanding of 
interactions between estradiol and inhibitory signals during TTFR has the potential to provide 
important insights for weight control in humans.  
   
Estradiol Effects on Body Weight and Uterine Weights   
In this study, ad libitum fed rats that were EB-treated weighed less than did OIL-treated 
rats throughout the three weeks of the study (Figure 4a).  These findings of weight loss in 
EBtreated rats but weight gain in OIL-treated rats (Figure 3) are consistent with previous work in 
our lab and others (48, 79). In addition, uteri assessed three weeks after EB-treatment were 
hypertrophied as compared to those in OIL-treated rats (Figure 2).  These measures serve as 
bioassays to demonstrate the efficacy of the EB-treatment.   
  
Estradiol Effects on Chow intake and Body Weight during TTFR  
During ad libitum access to chow, the intake that occurred overnight appeared to be 
satiating, as neither EB- nor OIL-treated group ate appreciable amounts of chow during 2 hour 
tests conducted during the day (Figure 6). In contrast, both EB-treated and OIL-treated rats 
consumed substantial amounts of chow in 2-hour intake tests during TTFR. Given numerous 
reports from our lab and others that EB decreased food intake (8, 10, 22, 48, 64, 88), it was 
surprising that OVX rats given EB ate the same amount of chow as did rats given OIL. These findings 
suggest that estradiol affects feeding during TTFR differently than it does during ad libitum access 
to chow. Thus, one would predict changes in body weight that reflect eating.  
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However, even though EB-treated rats weighed less than OIL-treated rats at the end of the ad 
libitum feeding period, and despite substantial body weight loss during TTFR in both groups, 
particularly on the first day (Figure 4b), EB-treated rats lost more weight throughout TTFR than 
did OIL-treated rats (Figure 5).    
  
Mechanisms Underlying Estradiol Effects during TTFR  
  
Estradiol effects on gastric and central mechanisms  
During ad libitum feeding conditions, EB decreases chow intake by decreasing meal size 
(17, 64). This effect is thought to be due, in part, to enhanced sensitivity to gastric distension 
and/or the gut hormone, CCK (9, 37, 49-51, 111). In the present study, both OIL- and EB-treated 
rats consumed substantial amounts of chow during TTFR. In fact, amounts of chow consumed in 
2-hour intake tests were approximately half the amounts typically consumed by rats during 24 
hours of ad libitum access to chow (76), but far in excess of what would typically be consumed in 
a single meal during ad libitum feeding (8, 17). These intakes likely generated considerable gastric 
distension and, thereby, considerable activation of stretch receptors that send inhibitory signals 
to the NTS (45, 86, 119). The consumption of such large amounts of chow by OIL- and EB-treated 
rats in the 2-hour intake tests during TTFR suggests that both OIL- and EB-treated rats were less 
sensitive to inhibitory signals, particularly those related to gastric distension.  Consistent with this 
idea, both the sensitivity (86) and the phenotype of gastric vagal afferents (45) depend on feeding 
condition and the amounts of food consumed. Even with such changes, however, extreme gastric 
stretch due to consumption of large amounts of chow such as we observed in the 2-hour intake 
tests would be expected to increase vagal signaling to the CNS and, ultimately, to terminate 
feeding (39, 86).   
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Gastric stretch is detected by vagal afferent fibers arising in the stomach that terminate  
in the NTS  (33) and stimulation of those fibers produces neuronal activation in the NTS (24, 45, 
50, 51, 64, 79).  Therefore we opted to employ immunohistochemical labeling of the fos protein 
as a strategy to assess neuronal activation in the NTS in response to consumption of chow during 
TTFR (Figure 9a,b,c). There was little fos immunolabeling in the NTS of EB- or OIL-treated rats that 
had ad libitum access to chow and therefore ate little in the test before euthanize. Similarly, fos 
immunolabeling in the NTS of rats on TTFR that were not permitted to eat before euthanize 
(fasted) was sparse (50), an important finding which suggests that the TTFR itself did not elicit 
neuronal activation in the NTS. In contrast, fos immunolabeling in the NTS of rats on TTFR that 
were permitted to eat before euthanization (fed) was elevated, but there was no difference 
between hormone treatments. This finding suggests no difference in the detection of inhibitory 
gastric distension signaling attributable to estradiol.   
Since our experimental design was intended to mimic eating patterns of some obese and 
overweight people who often eat only one large evening meal, we restricted the time rats were 
permitted to eat, rather than restricting the amount of chow provided. This approach revealed 
similar food intake and fos immunolabeling after EB-treatment. In contrast, Eckel and colleagues  
(50), reported greater fos labeling in EB-treated rats for which meal size was controlled so both 
EB- and OIL-treated groups ate the same amount under ad libitum conditions.   
Estrogen effects on feeding under ad libitum feeding conditions are mediated in part by binding 
to the  subtype of ER in the NTS (162).  We saw no differences in the ERα immunolabeling in the 
midNTS or cNTS as a result of feeding condition or hormone treatment (Figure 8a,b,c).  Thus, there 
no differential effect of either TTFR or EB-treatment on ERα numbers in the NTS, suggesting food 
intake during TTFR does not involve ERα signaling in the NTS. Though ERα and fos labeling were 
not done in the same tissue sections because the primary antibodies were raised in the same 
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animal, I found less ERα labeling in both the cNTS and midNTS than fos labeling.  This suggests 
that there are more neurons activated (fos labeled) under the tested conditions than there were 
neurons containing ERα. It is possible that ERα in other CNS areas may play a role in the control 
of feeding with TTFR and ongoing studies will address that issue.   However, it should be noted 
that ERα numbers may not reflect affinity of the receptors to bind estradiol.  Thus, we cannot rule 
out a role for ERα in the control of feeding during TTFR, though it seems unlikely that this involves 
ERα in the NTS.  
Together, these findings suggest that, during TTFR, EB has no effect on food intake or in 
the processing of signals related to the control of feeding at the level of the NTS.  However, this 
interpretation rests on the assumption that the ingested chow is emptied from the stomach at 
comparable rates.  In other words, even though food intake was similar between the hormone 
conditions during TTFR, it is possible that gastric emptying was different.  Estrogen has been 
reported to decrease gastric emptying (25). Therefore, we weighed stomach contents on day four 
of TTFR as an indicator of gastric emptying and found no differences between EB- and OIL-treated 
rats (Figure 7).  These findings suggest that there are no differences in stretch signals or processing 
of food through stomach between EB-treated and OIL-treated rats during TTFR.    
In summary, then, our observation that numbers of fos immunolabeled neurons in the 
NTS of EB-treated rats were comparable to that in OIL-treated rats suggests that, unlike EB effects 
during ad libitum conditions, detection of meal-induced inhibitory signals in the NTS after TTFR is 
not affected by EB.  However, although neural activation was not quantitatively different, different 
types of neurons may be activated.   If this is the case the effect is unlikely to be attributable to 
ERα in the NTS which were not affected by EB-treatment with or without TTFR.  
    




Since changes in neither CNS processing nor gastric emptying are associated with EB 
effects during TTFR, it is possible that estrogen-mediated differences in metabolism could explain 
the difference in EB effects during TTFR, especially in regard to body weight loss.  Accordingly, we 
investigated effects of EB treatment on carbohydrate and fat metabolism.  In these studies we 
focused on primary metabolites associated with carbohydrate and fat metabolism, and on 
hormones related to metabolism of carbohydrates and fats.    
  
Carbohydrate metabolism  
Insulin is a major regulator of glucose levels in carbohydrate metabolism.  Plasma insulin 
levels were not different between OIL-treated and EB-treated rats (Figure 10) but were 
significantly different between feeding conditions.  Specifically, insulin levels in OIL-treated and 
EB-treated rats in the ad lib groups approximated physiological values, as also reported in other 
studies (56), with a trend towards lower levels in EB-treated rats.  Insulin levels in both fasted 
groups were reduced as expected, given the decrease in glucose influx during TTFR with fasting.  
In contrast, insulin was restored to ad libitum levels within the short (one hour) time of refeeding 
in both hormone groups, presumably because of increased glucose influx.  Thus, the hormonal 
regulator of glucose homeostasis, insulin, was not affected by EB-treatment during TTFR. To 
investigate circulating carbohydrates, we first measured plasma glucose in the OIL- and EBtreated 
rats.  Figure 11 shows that glucose levels were significantly less in EB-treated rats, independent of 
feeding condition.  This decrease in plasma glucose with EB treatment has been previously 
reported (105).  However, the decreased glucose was not to the point of hypoglycemia and, in fact 
glucose is tightly regulated since this is a critical metabolite for brain function.  
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Nonetheless, the lower glucose levels in EB-treated animals may reflect an overall increase in 
metabolic rate, or possibly impaired gluconeogenesis leading to differences in glucose stored as 
glycogen.   
Stored carbohydrate in the form of liver glycogen (Figure 12) was reduced in the fasted 
condition of both EB- and OIL-treated rats likely because it is utilized to maintain plasma glucose 
levels during TTFR.  However, glycogen levels were partially restored within one hour after eating 
to about half the levels observed during ad libitum conditions in OIL-treated rats.  The increase 
after eating in EB-treated rats was somewhat blunted (only to about a quarter of that during ad 
libitum conditions), though this difference was not significant.  In fact, there was no effect of 
EBtreatment on liver glycogen.  Thus, differences in carbohydrate metabolism do not appear to 
be an important factor determining reduced body weight of EB-treated rats during TTFR.  
  
Lipid metabolism  
The hormone leptin is released from adipocytes and is proportional to body adiposity. 
Despite decreased body weight in EB-treated rats during both ad libitum conditions and TTFR, EB 
did not affect circulating leptin, though there was a tendency toward reduced levels. In contrast, 
feeding condition exerted a profound effect on leptin (Figure 13).  Plasma leptin during ad libitum 
conditions was within physiological range as previously reported (172) and leptin levels in the TTFR 
fasted groups were reduced, presumably because of the decreased adiposity in fasted animals.  
Interestingly, leptin levels in TTFR fasted groups were restored to nearly ad libitum levels within 
the short refeeding time period. This effect may be attributable to the intraluminal source of leptin 
(11, 27, 157).  Thus, there appears to be a rapidly occurring increase in leptin which originates in 
the GI tract, in addition to the leptin from adipose tissue which serves as a long-term adiposity 
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signal. In any case neither the intra-luminal nor the adipose leptin was affected by estrogen in 
these studies.  
A role for estrogen in fat metabolism during TTFR is suggested by previous studies of both 
women and rats (105).  In those studies of EB-treated of OVX rats or postmenopausal women, 
fasted plasma triglycerides were elevated.  I found that plasma triglycerides in EB-treated rats 
were greater in all feeding conditions compared to OIL-treated controls, an observation that may 
be due to the slight decrement in insulin levels with EB treatment that likely reduces lipolysis.  In 
addition, feeding condition affected plasma triglycerides with TTFR-fasted groups having less 
triglycerides than did ad libitum and TTFR-fed groups. These data suggest that the triglycerides 
are being utilized for energy during fasted conditions in both EB- and OIL-treated rats.  However, 
plasma triglycerides were restored to levels comparable to those in ad libitum conditions within 
one hour after eating during TTFR.  Thus, EB-treatment increases triglycerides, but the triglyceride 
levels nonetheless exhibit a pattern of changes during TTFR similar to that observed in OIL-treated 
rats (Figure 14).  
  Like plasma triglycerides, plasma FFA were elevated in the EB-treated animals 
independent of feeding condition (Figure 15a).  In addition, independent of hormone condition, 
plasma FFA in TTFR-fasted groups were greater than ad libitum and TTFR-fed groups.  These 
observations suggest that FFA are not recruited for energy metabolism in TTFR-fasted animals.  
Rather, the elevated FFA in the TTFR-fasted groups may derive from the breakdown of the 
triglycerides, which are less in the TTFR-fasted groups.  Given the difference in ad libitum levels of 
FFA between EB- and OIL-treated rats, we decided to investigate change in plasma FFA.   The 
change calculated was less in EB-treated rats than it was in OIL-treated rats (Figure 15b), 
suggesting less change in plasma FFA during TTFR in EB-treated rats.   
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 Adipose triglycerides were not affected by either hormone group or feeding condition 
(Figure 16).  Thus, this source of energy does not seem to be utilized during TTFR.  Adipose 
triglycerides in EB-treated TTFR groups tended to be less than those in the ad libitum EB-treated 
group.  This may suggest a slower rate of uptake for the triglycerides into adipose tissue, which 
would be consistent with increased plasma triglycerides in EB-treated rats.  Alternatively, lipolysis 
and mobilization of FFAs may be accelerated in EB-treated rats during TTFR.  
  
Corticosterone/adrenals  
 It is known that the stress hormone, corticosterone also affects carbohydrate, fat and 
protein metabolism.  This observation is particularly important since the TTFR schedule may serve 
as a physiological stressor.  Thus, we weighed adrenal glands and assayed plasma corticosterone 
in this study. The adrenals were significantly hypertrophied in the EB-treated group compared to 
the OIL-treated controls and weighed more in the TTFR groups than in the ad libitum groups, 
regardless of hormone (Figure 17).  Not surprisingly, given the brief feeding period, adrenal 
weights in TTFR-fed and TTFR-fasted groups were not different. Thus, the increase in adrenal 
weight in the EB-treated groups may be an indication of physiological stress during TTFR that is 
exaggerated by estrogen.  
  Plasma corticosterone levels were greater in EB TTFR-fasted and EB TTFR-fed groups than 
OIL TTFR-fasted and OIL TTFR-fed groups, as shown in Figure 18, possibly indicating EB treatment 
acts as a stressor under these conditions. Additionally, however, plasma corticosterone in EB  
TTFR-fasted and EB-TTFR-fed groups were greater than the EB ad libitum corticosterone level.  The 
EB TTFR-fed group plasma corticosterone was greater still than that in EB TTFR-fasted group.  The 
fed condition had the highest corticosterone level and thus, not only TTFR but also the 
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consumption of a large meal appears to be a physiological stressor.  There was no difference in 
the plasma corticosterone levels in any of the OIL-treated feeding conditions.  Apparently the 
EBtreatment per se was not responsible for the stress since the ad libitum EB-treated group 
plasma corticosterone was not different from that of the OIL-treated groups.  Thus, in EB-treated 
rats, increased corticosterone may be responsible for differences in lipid metabolism, increased 
basal metabolism and thereby decreased body weights.   
  
Summary  
In summary, EB-treatment during TTFR reduces body weight without decreasing the 
amount of food eaten.  This finding was not explained by CNS effects or gastric processing. 
Investigations of peripheral metabolic status of these animals, revealed no differences between 
EB- and OIL-treatment in the carbohydrate/insulin condition of these rats nor was leptin different 
between hormone groups. However, FFA and TG were elevated in EB-treated rats. These findings 
suggest that these EB-treated rats are utilizing lipids as did male rats on the TTFR protocol (70). In 
that study, the large load of nutrients taken in during TTFR were not stored as glycogen. Rather, 
these newly synthesized lipids, were presumably used as fuels, a shift that was proposed to be 
due to adapting to TTFR. This adaptation involved catabolizing fat as the major energy source and 
limiting glucose utilization to the small amounts required by the CNS (70).  Finally, thus, elevated 
corticosterone in the EB-treated TTFR rats may increase the basal metabolic rate (40) resulting in 
greater and more efficient energy utilization, particularly of fats, and thus, decreased body 




Future Directions  
  To further these experiments, I would increase the duration of TTFR to three or four weeks 
to see if the weight difference between EB-treated and OIL-treated rats persists.  I expect the 
amount eaten in a two hour period may increase to a point of stomach fullness above which it 
cannot go further. At that point, not only the amount eaten but also the weight loss may be the 
same between the groups, a fundamental change in the way estrogen effects the controls of 
weight loss and food intake.  
  I would also want to understand the underlying mechanism behind the weight differences 
despite similar food intake.  Experiments in which dexamethasone would be used to block the 
corticosterone increase and thereby eliminate differences in lipid metabolism could be 
conducted.  Additionally, if as I propose, corticosterone increases basal metabolic rate, the rates 
of metabolism could be measured by various techniques including assessment of VO2 max.  
Alternatively, an indicator of increased energy expenditure that could contribute to the increased 
body weight loss is to assess locomotor activity by video-taping the rats during the TTFR period.   
 All of these measures would serve to add to the conclusions of these experiments and 
lead to other questions.  As always, there are more questions to be asked than there are people 
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